![]() |
|
|
Forward to a colleague |
||
Access Full Stories Pfizer is vowing to fight on as Nigerian court battles against its subsidiary in the country wage on over its alleged involvement in child deaths through experimentation over a decade ago... Read Cambrex makes Estonian API biz buy Cambrex' Swedish arm has agreed to purchase ProSyntest, an Estonian active pharmaceutical ingredients (API) research and development company... Read Thousands of rodents saved from drug testing Thousands of rodents lives will be saved each year after a specific animal test is being scrapped following a review by 18 pharmaceutical companies... Read Former ICOS plant finds new home with Saltigo Chemical and intermediates firm Lanxess has announced that its subsidiary Saltigo is the proud new owner of a site in Washington in the US, formerly used by Eli Lilly subsidiary, ICOS... Read eclinical news in brief Outsourcing-Pharma tracks the latest eClinical movements, featuring Medidata, UBC, Tessella and Datatrak... Read |
||||||||||||||
All News Headlines for: January | December | November |
||||||||||||||
![]() Almac improves IMP blinding services Almac Clinical Services now offer enhanced encapsulation and blinding services. Almac provides fully automated over-encapsulation for capsule batches of hundreds to millions and also a range of blinding options for inhaled products... Click Here | ||||||||||||||
|
Related Industry News Funding shot for cell-based vaccines A major grant has been awarded to a UK consortium working to develop predictive manufacturing tools for cell-based cancer vaccines... Read JAMA article boosts Novartis meningitis jab Novartis has been keen to shout about data published this week in the Journal of the American Medical Association (JAMA) that backs up claims that it has developed the first vaccine to protect infants against the... Read US approval for once daily Cialis Eli Lilly's once-a-day version of its erectile dysfunction (ED) treatment Cialis (tadalafil) has finally got the go ahead from US regulators, six months after approval in the EU... Read Crucell, Sanofi mix it up with rabies cocktail deal Dutch firm Crucell last week announced that it has entered into an agreement with vaccine specialist Sanofi Pasteur for its next generation rabies antibody cocktail... Read
|
||||||||||||||
|
|||||
Forward to a colleague |
|||||
To continue to receive this newsletter in your inbox, please add newsletter@OutSourcing-Pharma.com to your address book |
||
Update preferences | Change your email address | Unsubscribe |
||
Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback |
||
| © 2008 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com |
||